Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS Pharma

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

Combatting EU drug shortages

New guidelines to be issued after EMA report

AstraZeneca AZ

AZ looks beyond diabetes with Forxiga trials

Will investigate dapagliflozin in kidney disease and heart failure

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

AstraZeneca AZ

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British Lung Foundation and MRC Technology

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

- PMLiVE

AstraZeneca adds cardiovascular resources to online diabetes programme

Expansion of Fit2Me also includes new Apple and Android mobile apps

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links